Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

This news of Ozempic price cuts comes on the heels, or tablet, of Novo Nordisk developing a weight loss pill that mirrors the ...

While the race for the next big weight loss solution heats up, a Danish pharmaceutical company says its oral weight loss drug ...

Amycretin mimics the actions of glucagon-like peptide-1 (GLP-1) and amylin, hormones that play a role in reducing blood sugar ...

Amycretin, an oral weight loss pill developed by the makers of Wegovy, led to a 13.1% weight loss over three months in early ...

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued ...

A daily diet pill has shown promising results in early trials, with participants losing an average of 13% of their body ...

Terns Pharmaceuticals (NASDAQ: TERN) is one of them. The fledgling clinical-stage drugmaker recently reported positive ...

FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy. Novo Nordisk (NVO) reachead $136.66 at the closing of the ...

A new weight loss pill called amycretin has helped people lose up to 13% of their body weight in just three months, according ...

Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule ...